Natco Pharma Ltd

Natco Pharma Ltd

Natco Pharma Ltd has announced the voting results of its 43rd Annual General Meeting, with all resolutions passed with high voting percentages. The company has also announced the re-appointment of a director and the ratification of the remuneration of cost auditors. Additionally, the company has sought shareholder approval for raising funds up to Rs. 2,000 crores through various means.

Natco Pharma Ltd

Natco Pharma Ltd has announced the closure of its trading window for directors, designated persons, and their relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ending September 30, 2026.

Natco Pharma Ltd

Natco Pharma Ltd held its 43rd Annual General Meeting on September 30, 2026, through video conference. The meeting was attended by 51 members, and the company's Chairman and Managing Director, V.C. Nannapaneni, conducted the proceedings. The meeting approved the audited annual financial statements for FY 2025-26, confirmed three interim dividends, and re-appointed a director. The company also announced plans to raise up to ₹2,000 crores through various methods.

Natco Pharma Ltd

Natco Pharma Ltd has announced the approval of the Letter of Offer for its Rights Issue, which will issue up to 17,058,082 equity shares at ₹750 per share to eligible equity shareholders.

Natco Pharma Ltd

Natco Pharma Ltd has increased its investment in eGenesis, Inc. from $14 million to $16.70 million through its wholly owned subsidiaries. eGenesis is a biotechnology company focused on using its multiplex gene editing and genome engineering platform to transform solid organ and therapeutic cell transplantation for the treatment of serious diseases.

Natco Pharma Ltd

Natco Pharma Ltd has published a newspaper advertisement announcing the record date for its rights issue, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Natco Pharma Ltd

Natco Pharma Ltd has announced the record date for its rights issue, set as Thursday, 1st October, 2026, to determine the shareholders eligible to receive the rights entitlements.

Natco Pharma Ltd

Natco Pharma Ltd has announced the outcome of its Board Meeting, where it has approved the issuance of equity shares through a rights issue to eligible equity shareholders. The rights issue will be for an amount not exceeding ₹12,79,35,61,500 and will be priced at ₹750 per rights equity share.

Natco Pharma Ltd

Natco Pharma Ltd has informed the Exchange that its Board of Directors has decided to issue equity shares on rights basis in the ratio of 2:21, with an issue price of Rs. 750 per share, for an amount not exceeding Rs. 12,79,35,61,500.

Natco Pharma Ltd

Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 25/09/2026 to consider and approve the specific terms of the Rights Issue, including the determination of the Rights Issue price and related payment mechanism.

Natco Pharma Ltd

Natco Pharma Ltd has received in-principle approval from National Stock Exchange of India Limited and BSE Limited for the Rights Issue of fully paid-up equity shares.

Natco Pharma Ltd

Natco Pharma Ltd has announced an investor meet on September 7, 2026, in Hyderabad, where company officials will interact with investors. The meeting schedule is subject to change.

Natco Pharma Ltd

Natco Pharma Ltd's promoter, Durga Devi Nannapaneni, has gifted 50,000 equity shares to her niece, Smt. G. Kalajyothi, resulting in a decrease in her shareholding from 1.98% to 1.95%.

Natco Pharma Ltd

Natco Pharma Limited has invested US$ 14 million in eGenesis, Inc. through convertible promissory notes, taking its total investment to US$ 22 million. eGenesis is a biotechnology company focused on using its multiplex gene editing and genome engineering platform to transform solid organ and therapeutic cell transplantation for the treatment of serious diseases.

Natco Pharma Ltd

Natco Pharma Ltd has announced an investor meet, where company officials will participate in discussions with investors. The meet will be held on various dates in August 2026, and the company's latest investor presentation is available on its website.

Natco Pharma Ltd

Natco Pharma Ltd has concluded the US FDA inspection at its Visakhapatnam, Andhra Pradesh, Finished Dosage Formulations (FDF) Unit, with 4 observations on a Form 483. The company believes the observations are procedural in nature and is confident of addressing them within stipulated timelines.

Natco Pharma Ltd

Natco Pharma Ltd announced an investor meet on August 24, 26, and 27, 2026, in Singapore, organized by Nuvama Wealth Management and ICICI Securities Limited. The company's officials will participate in the meeting to discuss the latest investor presentation, available on the company's website.

Natco Pharma Ltd

Natco Pharma Ltd has made an investor presentation, which is a general background information about the company's activities as of the date of the presentation.

Natco Pharma Ltd

Natco Pharma Ltd's Q1 FY27 earnings conference call transcript is available on the company's website, discussing financial highlights, including a decline in consolidated total revenues and an improvement in EBITDA margin.

Natco Pharma Ltd

Natco Pharma Ltd has announced an investor meeting organized by Nuvama Wealth Management Limited and ICICI Securities Limited on August 19th and 21st, 2026, in Mumbai. The meeting is not intended to discuss unpublished price sensitive information.